Entrar/Registro  
HOME SPANISH
 
Gaceta Médica de México
   
MENU

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board






>Journals >Gaceta Médica de México >Year 2013, Issue 5


Pavón-Sánchez JM, Sánchez-Sánchez LM
Rituximab in pediatric patients with systemic lupus erythematosus
Gac Med Mex 2013; 149 (5)

Language: Español
References: 21
Page: 492-496
PDF: 79.83 Kb.


Full text




ABSTRACT

Systemic lupus erythematosus (SLE) is an autoimmune disease that is more severe in pediatric population than in adults. Biological therapy with anti-CD20 (rituximab) in children with SLE was begun to use only a few years ago, in patients that do not respond to conventional therapy. The aim of this study is to determine the clinical response in pediatric patients with SLE that received treatment with rituximab in a third level hospital. Results: Eight pediatric patients with SLE treated with rituximab were included. Female gender predominated with six (75%). The age at diagnosis of SLE was a mean of 11.3 ± 1.03 years. The mean time between the onset of symptoms and diagnosis was 4.12 ± 1.01 months, and the application of rituximab was 20.7 ± 6.2 months after diagnosis. The most common diagnostic criteria were: malar erythema, hematologic disease, arthritis and kidney disease. Positive ANA title was found in 62.5% of the patients. The clinical activity index MEX-SLEDAI before rituximab was 11.63 ± 6.8 points. Four patients (50%) died, they had activity index before rituximab of 23 ± 1.7 and the survivors of 12.2 ± 3.2 (p = 0.002). After treatment with rituximab the patients that died had 17.6 ± 8.5 points and the survivors 8 ± 2.1 (p = 0.038). In laboratory findings, only C3 and C4 had a significant change after treatment (p = 0.048 and 0.032). Conclusions: Rituximab reduces lupus activity index and increases complement levels in children with LES that don’t respond to conventional therapy


Key words: Systemic lupus erythematosus, Rituximab, Clinical activity index of SLE.


REFERENCIAS

  1. Blancas L, Guevara M, Espinosa F. Lupus eritematoso sistémico en niños. Alerg Asma Inmunol Pediatr 2009;19(1):6-9.

  2. Silverman E, Eddy A. Systemic Lupus Erythematosus. En Textbook of Pediatric Rheumatology. Cassidy JT, Petty RE (Eds.), Elsevier Saunders., 6.a ed., Philadelphia, EUA, 2011, p. 315-43.

  3. Escobar-Picasso E, Espinosa-Huerta E, Moreira-Ríos M, Tratado de Pediatría. El niño enfermo. 1.a ed. México, D.F.: Manual Moderno, 2006. p. 1313-9.

  4. Davila L, Ranganathan P. Pharmacogenetics: implication for therapy in rehumatic diseases. Nat Rev Rheumatol. 2011(7):537-50.

  5. Willems M, Haddad E, Niaudet P. Rituximab Therapy for childhood-onset systemic lupus erytematosus. J Pediatr 2006;148:623-7.

  6. Hiraki LT, Benseler SM, Tyrrell PN, et al. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr 2008;152(4):152-550.

  7. Schmugge M, Revel-Vilk S, Hiraki L, Rand ML, Blanchette VS, Silverman ED, Thrombocytopenia and thromboembolism in pediatric systemic lupus erythematosus. J Pediatr 2003;143:666-9.

  8. Ortega-Álvarez SM, Rubio-Pérez N, Yáñez-Pérez IV. Lupus neuropsiquiátrico en edad pediátrica. Medicina Universitaria. 2010;12(47):125-30.

  9. Ravelli A, Ballardini G, Viola S, Villa I, Ruperto N, Martini A. Methotrexate therapy in refractory pediatric onset systemic lupus erythematosus. J Rheumatol. 1998;25:572-5.

  10. Caggiani M, Gazzara G. Lupus eritematoso sistémico en niños y adolescentes. Características clínicas, inmunológicas y evolutivas. Análisis y consideraciones terapéuticas. Arch Pediatr Urug. 2003;74(4):237-44.

  11. Marks SD, Tullus K. Modern therapeutic strategies for paeditric systemic lupus erytematousus and lupus nephritis. Acta paediatrica. 2010; 99:957-74.

  12. González B, Hernández P, Olguín H, Miranda M, Lira L, Toso M, Quezada A, Norambuena X, Talesnik E, Méndez C, Navarrete C. Changes in the survival of patients with systemic lupus erythematosus in childhood: 30 years experience in Chile. Lupus. 2005;14(11):918-23.

  13. Guzmán J, Cardiel MH, Arce-Salinas A, Measurement of Disease Activity in Systemic Lupus Erythematosus. Prospective Validation of 3 Clinical Indices. J Rheumatol. 1992;19:1551-8.

  14. Looney RJ, Anolik J, Sanz I. Treatment of SLE with Anti-CD20 Monoclonal Antibody. Curr Dir Autoimmun. 2005;8:193-205.

  15. Fra GP, Avanzi GC, Bartoli E. Remission of refractory lupus nephritis whit a protocol including rituximab. Lupus. 2003;12:783-7.

  16. Garcia-Hernandez FJ, Díaz-Cobos C, Callejas-Rubio JL, Ocaña-Medina C, Ortego-Centeno N, Sánchez-Roman J, et al. Experiencia con rituximab en el tratamiento de pacientes con lupus eritematoso sistémico. Reumatol Clin. 2006;2:23-30.

  17. Weiss JE. Pediatric Systemic Lupus Erythematosus: more than a positive antinuclear antibody. Pediatrics in Review 2012;33 (62) DOI: 10.1542/pir.33-2-62.

  18. Iwata S, Saito K, Tokunaga M. Phenotypic Changes of lynphocytes in patients with systemic lupus erytematosus who are in longterm remission after B cell depletion therapy with rituximab. J Rheumatol. 2011;38:633-41.

  19. Podoslskaya A, Stadermann M, Pilkington C, Marks SD, Tullus K. B cell depletion therapy for 19 patients with refractory systemic lupus erytematosus. Arch Dis Child. 2008;93:401-6.

  20. Gillis JZ, Dalloera M, Gross A, Yazdany J, Davis J. Six refractory lupus patients treated with rituximab: a case series. Arthritis Rheum. 2007;57:538-42.

  21. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology. 2001;40:205-11.






>Journals >Gaceta Médica de México >Year 2013, Issue 5
 

· Journal Index 
· Links 






       
Copyright 2019